MLYS logo

MINERALYS THERAPEUTICS INC

MLYSNASDAQ
🏆 #1902 by market capEarnings Nov 9US Equity
$182.94▲ $0.90 (+0.49%)
Simulated price
🔔
Track MLYS
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$2.26B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak
No chart data available for MLYS.

Trading Snapshot

Day Range
$180.34 – $185.35
52-Week Range
$22.30 – $47.65
Volume
$2.55B
Avg Volume
$2.99B
Shares Outstanding
88.2M
Next Earnings
Nov 28, 2026

Fundamentals Snapshot

Annual Revenue
$195M
Last Q Revenue
$51M
P/E Ratio
-6.0
P/S Ratio
0.0x
EPS (TTM)
$-4.13
Dividend Yield
0.00%
Dilution (1yr)
+61.2%

Why Investors Own MLYS

  • ✓High-growth profile — revenue up +24.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 25% gross margin and 11% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MLYS logo

MINERALYS THERAPEUTICS INC

MLYS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$171M▼ −11.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$142M▼ −14.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
80.5M▲ +61.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$173M▲ +$59M YoY
StockOtter · stockotter.space

About MINERALYS THERAPEUTICS INC

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$206.00
▲ +12.6% Upside
High Target$226.32
Low Target$160.46
Based on 14 analysts

Latest News & Updates

🚀
Reuters·2h ago

MINERALYS THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift MLYS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

MINERALYS THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.